Myelofibrosis Clinical Trials

32 studies are recruiting for myelofibrosis in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. AlloHCT With PegINFa for Myelofibrosis

   This is a single site, open-label, dose de-escalation, Phase 1 study of pegylated interferon alfa-2a administered after alloHCT in subjects with primary or secondary myelofibrosis. Part 1 of the study will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and ident…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah

   Run by

   University of Utah

   See if you can join NCT05535764 on ClinicalTrials.gov

2. Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

   This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Locations

   3 in total

   Run by

   John Mascarenhas

   See if you can join NCT07447817 on ClinicalTrials.gov

3. Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow

   This is a phase I/II protocol investigating whether Nelfinavir can improve anemia and lower serum fibrosis biomarkers in Myelofibrosis patients.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

   Run by

   University of California, Irvine

   See if you can join NCT07281781 on ClinicalTrials.gov

4. CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

   This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. Th…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   3 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT06059391 on ClinicalTrials.gov

5. A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

   This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cel…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   3 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT07020533 on ClinicalTrials.gov

6. Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

   This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with myelofibrosis or myelodysplastic syndrome and anemia.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Banner MD Anderson, Gilbert, Arizona

   Locations

   35 in total

   Run by

   Disc Medicine, Inc

   See if you can join NCT05320198 on ClinicalTrials.gov

7. Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

   To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UC Davis Health, Sacramento, California

   Locations

   4 in total

   Run by

   Cellenkos, Inc.

   See if you can join NCT05423691 on ClinicalTrials.gov

8. Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis

   The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah

   Run by

   University of Utah

   See if you can join NCT07521046 on ClinicalTrials.gov

9. Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

   This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies (DSA) levels to low enough levels to permit patie…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT06398457 on ClinicalTrials.gov

10. A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

    This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama, Birmingham, Alabama

    Locations

    91 in total

    Run by

    Sumitomo Pharma America, Inc.

    See if you can join NCT04176198 on ClinicalTrials.gov

11. A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

    The main aim of this study is to find out how well elritercept works to improve anemia in participants with myelofibrosis (MF) who are taking ruxolitinib when compared to placebo. Other aims are to learn how elritercept improves anemia compared to placebo; to learn if elritercept reduces tiredness,…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Advanced Research, LLC, Coral Springs, Florida

    Locations

    195 in total

    Run by

    Takeda

    See if you can join NCT07623161 on ClinicalTrials.gov

12. High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

    To learn if giving ruxolitinib and busulfan before a stem cell transplant can help to reduce spleen size and help the transplant to succeed.

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06345495 on ClinicalTrials.gov

13. A Telehealth Advance Care Planning Intervention

    The objective of this project is to conduct a pilot randomized trial to assess the preliminary efficacy of a telehealth-delivered Serious Illness Care Program on healthcare communication, patient anxiety and distress, as well as completion of advance directives (specifically MOLST and healthcare pr…

    Stage

    Not phased

    Ages

    60 and older

    Site

    University of Rochester, Rochester, New York

    Run by

    University of Rochester

    See if you can join NCT05875805 on ClinicalTrials.gov

14. Quantitative MRI for Myelofibrosis

    This study is for the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis.

    Stage

    Not phased

    Ages

    18 to 99

    Site

    University of Michigan Hospital, Ann Arbor, Michigan

    Run by

    University of Michigan Rogel Cancer Center

    See if you can join NCT01973881 on ClinicalTrials.gov

15. A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

    The researchers are doing this study to find out whether the combination of ruxolitinib and ulixertinib is a safe and effective treatment for people with myelofibrosis. The researchers will test different doses of ulixertinib to find the highest dose that causes few or mild side effects in particip…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital (Data Collection Only), Boston, Massachusetts

    Locations

    9 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06773195 on ClinicalTrials.gov

16. A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

    The purpose of this study is to test the safest and most effective dose of a new investigational drug, rebecsinib. Participants in this study will have either Secondary Acute Myeloid Leukemia (sAML) that has either returned (relapsed) or not responded to treatment (refractory) or have higher risk M…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope Center, Duarte, California

    Locations

    3 in total

    Run by

    Aspera Biomedicines, Inc.

    See if you can join NCT07250646 on ClinicalTrials.gov

17. Allo HSCT Using RIC and PTCy for Hematological Diseases

    This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamid…

    Stage

    Phase 2

    Ages

    Up to 75

    Site

    Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

    Run by

    Masonic Cancer Center, University of Minnesota

    See if you can join NCT05805605 on ClinicalTrials.gov

18. Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

    This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVH…

    Stage

    Phase 2

    Ages

    Up to 60

    Site

    Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

    Run by

    Masonic Cancer Center, University of Minnesota

    See if you can join NCT03314974 on ClinicalTrials.gov

19. Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

    The purpose of this study is to determine if hyperbaric oxygen therapy is safe in the setting of stem cell transplantation. This study will also determine if hyperbaric oxygen therapy improves engraftment, graft versus host disease, neutrophil count, and incidence and severity of mucositis (inflamm…

    Stage

    EARLY_Phase 1

    Ages

    18 to 75

    Site

    Wilmot Cancer Institute, University of Rochester, Rochester, New York

    Run by

    Omar Aljitawi

    See if you can join NCT03964506 on ClinicalTrials.gov

20. Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

    This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

    Stage

    Phase 1

    Ages

    13 and older

    Site

    University of Chicago, Chicago, Illinois

    Locations

    8 in total

    Run by

    Newave Pharmaceutical Inc

    See if you can join NCT04771572 on ClinicalTrials.gov

21. A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

    The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown …

    Stage

    Phase 3

    Ages

    18 and older

    Site

    University of Michigan ( Site 6000), Ann Arbor, Michigan

    Locations

    21 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT06351631 on ClinicalTrials.gov

22. Momelotinib During and After HCT in Myelofibrosis

    This is a single-center, open-label, phase I study to determine the safety and tolerability of momelotinib in patients with myelofibrosis during and after hematopoietic cell transplantation (HCT).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT07104799 on ClinicalTrials.gov

23. Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

    This phase II trial evaluates how a curcumin supplement (C3 complex/Bioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic syndrome (LR-MDS), and myeloproliferative neoplasms (MPN). Chronic infl…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Los Angeles General Medical Center, Los Angeles, California

    Locations

    2 in total

    Run by

    University of Southern California

    See if you can join NCT06063486 on ClinicalTrials.gov

24. A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

    The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who is not related and has a different blood cell type than the …

    Stage

    Phase 2

    Ages

    18 to 66

    Site

    University of Alabama Birmingham, Birmingham, Alabama

    Locations

    13 in total

    Run by

    Center for International Blood and Marrow Transplant Research

    See if you can join NCT06859424 on ClinicalTrials.gov

25. An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

    This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, Irvine, Irvine, California

    Locations

    2 in total

    Run by

    University of California, Irvine

    See if you can join NCT05123365 on ClinicalTrials.gov